Brookline Capital Markets Estimates UNCY Q2 Earnings

Key Points

• Brookline Capital Markets analyst K. Raja forecasts Q2 EPS of ($0.34) for Unicycive, while the consensus full-year earnings estimate is ($0.23) per share.
• Unicycive reported Q1 EPS of ($0.82) on March 30, missing the consensus of ($0.46) by $0.36, signaling a larger-than-expected loss.
• Analyst views are mixed but the consensus rating is a Moderate Buy with a target price of $25.67; UNCY shares trade near $6.45 (market cap ~$162.8M) and were recently down 3.4%.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Several other brokerages have also recently issued reports on UNCY. Guggenheim dropped their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, April 2nd. Westpark Capital began coverage on Unicycive Therapeutics in a research report on Thursday, February 19th. They issued a "buy" rating on the stock. Benchmark dropped their price target on Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating on the stock in a research report on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Unicycive Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.

Unicycive Therapeutics Stock Down 3.4%

Shares of UNCY stock opened at $6.45 on Thursday. The stock has a market capitalization of $162.80 million, a PE ratio of -2.97 and a beta of 1.81. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The stock's 50-day moving average price is $6.64 and its 200 day moving average price is $5.88.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. increased its position in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after purchasing an additional 21,525 shares during the period. Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics during the 4th quarter worth approximately $226,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth approximately $182,000. Finally, State Street Corp increased its position in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after purchasing an additional 10,400 shares during the period. Institutional investors and hedge funds own 40.42% of the company's stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.